key: cord-0887093-n4slrai8
authors: Farhadfar, Nosha; Burns, Linda J.; Mupfudze, Tatenda; Shaw, Bronwen E.; Bollard, Catherine M.; Devine, Steven M.; Horowitz, Mary M.; Jones, Richard J.; Murthy, Hemant S.; Wingard, John R.; Lee, Stephanie J.
title: Hematopoietic Cell Transplantation: Practice predictions for the Year 2023
date: 2020-10-09
journal: Biol Blood Marrow Transplant
DOI: 10.1016/j.bbmt.2020.10.006
sha: 4c2ce0bc3c1b6d5a7234591bdcaa2cf82cc524a9
doc_id: 887093
cord_uid: n4slrai8

BACKGROUND: Research priorities are best determined by the most pressing scientific questions, in the context of current knowledge. However, definitive research studies take time while real-world experience accumulates. Adoption of new practices before adequate comparison to current treatments threaten successful study conduct and may expose patients to what is ultimately learned to be inferior treatment. We conducted a survey to understand the Hematopoietic Cell Transplant (HCT) community's predictions about (a) future practice trends in the HCT field and (b) results of ongoing Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trials to gauge how the HCT community views the treatments being studied. METHOD: The survey was distributed between February and March 2019 to an electronic mailing list maintained by the Center for International Blood and Marrow Transplant Research (CIBMTR) of HCT clinicians practicing in the United States. RESULTS: Of 986 clinicians surveyed, 315 responded (32%). They predicted an increase in the number of HCTs performed for malignant hematologic diseases and benign diseases such as sickle cell, autoimmune and genetic disorders. The majority (63%) predicted that matched related donors (MRD) will remain the preferred donor source for adult HCT recipients in 2023 but 21% predicted haploidentical (Haplo) and 17% predicted matched unrelated donors (MUD) would be the preferred donors. Most respondents (65%) predicted a decrease in the use of umbilical cord blood (UCB) as a graft source for HCT. Most respondents also predicted that calcineurin-based graft-versus-host disease (GVHD) prophylaxis would be replaced by post-transplant cyclophosphamide (PTCy) (55%), biomarker use would become standard practice to guide GVHD therapy (73%), and steroids would be combined with other agents for first line therapy for newly diagnosed acute and (53%) chronic GVHD (54%). In ongoing BMT CTN trials where outcomes are not yet known, 60% to 92% of respondents had an opinion about which arm they thought would be superior. However, not all respondents predicted the same outcome with a range of 44% to 88% choosing the same arm. There was not a clear relationship between the proportion predicting the same arm would win and accrual to the trial. CONCLUSION: Survey respondents are optimistic about growth in the volume of transplant procedures, and they also expect significant changes in the practice of HCT over the next few years including wider adoption of PTCy GVHD prophylaxis, increased use of biomarkers to guide GVHD therapy, and decreased use of UCB HCT. The degree of equipoise in the community about the relative efficacy of therapies being studied did not seem to affect accrual to current BMT CTN trials but this is an area that needs further investigation.

Background: Research priorities are best determined by the most pressing scientific questions, in the context of current knowledge. However, definitive research studies take time while realworld experience accumulates. Adoption of new practices before adequate comparison to current treatments threaten successful study conduct and may expose patients to what is ultimately learned to be inferior treatment. We conducted a survey to understand the Hematopoietic Cell Transplant (HCT) community's predictions about (a) future practice trends in the HCT field and (b) results of ongoing Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trials to gauge how the HCT community views the treatments being studied. Results: Of 986 clinicians surveyed, 315 responded (32%). They predicted an increase in the number of HCTs performed for malignant hematologic diseases and benign diseases such as sickle cell, autoimmune and genetic disorders. The majority (63%) predicted that matched related donors (MRD) will remain the preferred donor source for adult HCT recipients in 2023 but 21% predicted haploidentical (Haplo) and 17% predicted matched unrelated donors (MUD) would be the preferred donors. Most respondents (65%) predicted a decrease in the use of umbilical cord blood (UCB) as a graft source for HCT. Most respondents also predicted that calcineurin-based graft-versus-host disease (GVHD) prophylaxis would be replaced by posttransplant cyclophosphamide (PTCy) (55%), biomarker use would become standard practice to guide GVHD therapy (73%), and steroids would be combined with other agents for first line therapy for newly diagnosed acute and (53%) chronic GVHD (54%).

In ongoing BMT CTN trials where outcomes are not yet known, 60% to 92% of respondents had an opinion about which arm they thought would be superior. However, not all respondents predicted the same outcome with a range of 44% to 88% choosing the same arm. There was not a clear relationship between the proportion predicting the same arm would win and accrual to the trial.

Survey respondents are optimistic about growth in the volume of transplant procedures, and they also expect significant changes in the practice of HCT over the next few years including wider adoption of PTCy GVHD prophylaxis, increased use of biomarkers to guide GVHD therapy, and decreased use of UCB HCT. The degree of equipoise in the community about the relative efficacy of therapies being studied did not seem to affect accrual to current BMT CTN trials but this is an area that needs further investigation. about what arm is superior. However, definitive research studies take time while real-world experience accumulates and new approaches are introduced. Adoption of new practices before they are adequately compared to current treatments threaten successful completion of studies and may expose patients to treatments that are ultimately determined to be inferior, or worse, are actually inferior but definitive evidence to determine that is never obtained. Here, we conducted a survey to understand HCT practitioners' predictions about future practice trends in the HCT field. In addition, by studying their predictions of the results of ongoing Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trials, we hoped to gauge how the HCT community views the treatments being studied and to gain insights into how that might affect accrual to these studies.

A description of the survey and an invitation to participate were emailed to HCT physicians who were actively practicing in the United States and had an email address on file with the Center for International Blood and Marrow Transplant Research (CIBMTR). The CIBMTR email listserv was reviewed by one investigator (N.F.) to remove participants who were not identified as HCT physicians.

The survey consisted of three sections. In the first, 14 questions collected information about participant and practice characteristics, including gender, age, experience, center geographic 

The survey was distributed to an electronic mailing list maintained by the CIBMTR, using Survey Gizmo (www.surveygizmo.com). The survey was open from 2/6/2019 to 3/9/2019. Four weekly email reminders were sent to all potential participants. Two drawings ($750 and $500 prizes) for respondents were held to incentivize participation.

Statistical analyses were performed using SAS 9.4. Descriptive statistics, including frequencies and percentages for categorical variables and means +/− standard deviation (SD) for continuous variables, to examine participants' responses to survey questions was used. Exploratory analyses were conducted using Fisher's exact tests, with Monte Carlo estimates of the exact P values to compare responses across characteristic categories; unadjusted P values were reported.

In addition, based on the planned accrual timeline of the BMT CTN trials determined at the launch of each trial, we were able to find out which BMT CTN trials enrollment lagged behind expectations. We then evaluated whether there is an association between strong community opinion about one arm or another and trial's accrual.

The survey was sent to potentially eligible subjects (N=1189) of whom 203 (17%) were not eligible to respond due to undeliverable or "out of office" e-mail (N=5) or confirmation that the recipient was ineligible (not a transplantation physician) (N=198). Of the 986 potentially eligible participants, 367 (37%) responded to the survey; 619 did not respond to email reminders, and we are unable to further classify this group into passive non-respondents versus inactive email addresses. Of the 367, 43 email recipients actively declined to participate in the study and 9 participants did not provide information beyond the "general information" section of the survey. The majority (66%) of participants had at least 10 years of experience as transplantation and cellular therapy physicians. A majority (67%) practiced at a BMT CTN core center. Nearly half (47%) of the participants were at centers performing a high volume (> 100 per year) autologous HCT. One third of the participants (33%) were at centers performing high volume (>100 per year) allogeneic HCT. Due to anonymity in responses, the characteristics of nonresponders are not available.

Participants were asked to provide predictions about the trends in HCT for malignant and nonmalignant hematologic diseases in the year 2023, as compared to 2018. In the entire cohort, nearly half of the participants predicted an overall increase in the number of HCTs performed for hematologic malignancies (Figure 1 ). Clinicians providing care for adults compared to those providing care for children (62% vs 28% respectively, p<0.0001), those practicing in high versus lower volume allogeneic (65% versus 41%, p =0.0003) and autologous HCT centers (64% vs 37% p <0.0001) and those practicing in BMT CTN core centers versus those who did not (57% vs 54%, p=0.001) were more likely to predict an increase in the numbers of HCT.

In the setting of hematologic malignancies, nearly 59% of respondents predicted that cellular therapy including chimeric antigen receptor (CAR) T-cell therapy will lead to a decrease in numbers HCT. Clinicians providing care for pediatrics compared to those providing care for adults (60% vs 55%, p=0.04) were more likely to predict that a decrease in the number of HCTs would occur due to the availability of new cellular or genetic therapies in the future.

Regarding non-malignant diseases, the majority predicted an increase in numbers of transplants for sickle cell disease (70%) and autoimmune diseases (64%). Clinicians providing care for pediatrics (83% vs 62%, p< 0.001) and practicing in non-BMT CTN core centers (77% vs 66%, p=0.017) were more likely to predict increases in HCT for sickle cell disease. Approximately half of the respondents predicted increases in the numbers of HCT for genetic disorders (51%), immunodeficiencies (49%) and regenerative medicine (42%). Approximately one-third anticipated that HCT would be used as a "standard of care" in systemic sclerosis (37%) or multiple sclerosis (35%) followed by systemic lupus erythematosus (12%), Crohn's disease (10%) and rheumatoid arthritis (6%).

The majority (63%) predicted that matched related donors (MRD) will remain the preferred donor source in adult (age ≥ 18 years) with acute myeloid leukemia (AML) undergoing allogeneic HCT in 2023 (Figure 2 ), 21% and 17% predicting that haploidentical (Haplo) or matched unrelated donor (MUD), respectively, would be the preferred donor source. Few respondents predicted umbilical cord would be the preferred donor source. Mis-matched unrelated donor (MMUD) was predicted to be preferred over umbilical cord in recipients who lacked MRD, MUD or Haplo donors by 53% of respondents. The majority of respondents (65%), irrespective of whether they care for children or adults, predicted a decrease in the numbers of umbilical cord transplants.

Survey respondents were asked to choose the most common donor source in 2023 for children (age < 18 years) with primary immune deficiency who lack a MRD (Figure 3 ). MUD was predicted to be the preferred donor source by 43% of participants, followed by Haplo TCRαβ+/CD19+depleted grafts (33%), Haplo with post-transplant cyclophosphamide (PTCy) (22%), and umbilical cord blood (11%) and MMUD (1%).

Respondents were queried about the use of newer transplantation strategies and treatments for the prophylaxis and initial management of acute and chronic GVHD. Clinicians caring for adults predicted a wider adoption of PTCy GVHD prophylaxis in 2023 ( Figure 4 ).

prophylaxis strategy for MUD HCT, followed by calcineurin-based prophylaxis (20%) and graft manipulation (10%). These results reflect a belief that the increased utilization of PTCy GVHD prophylaxis observed over the past decade would continue 2 . Physicians that practiced in high volume allogeneic HCT centers were more likely than those who practice in low volume centers to predict greater use of PTCy (75% vs. 45%, p < 0.0001). Among clinicians caring for children, the use of graft manipulation strategies (35%) was predicted to be the most common GvHD prophylaxis followed by PTCy (32%) and calcineurin-inhibitor based (30%) prophylaxis ( Figure   4 ).

The majority (73%) of respondents predicted that biomarkers, in addition to clinical features, would be used for both the diagnosis and risk stratification of acute and chronic GvHD.

Although respondents predicted that steroids will remain the front-line treatment of newly diagnosed acute GvHD, most predicted that steroids would be used in combination with other agents (55%) rather than as a single agent (28%). Similarly, the majority of respondents (53%) predicted steroids would be used in combination with other agents for newly diagnosed chronic GvHD. In contrast, nearly 20% of survey respondents predicted newer agents would be used for initial therapy of GvHD including infusions of regulatory cells, immunomodulatory molecules or antibodies, and this prediction was associated with practicing in a high-volume transplantation center (35% vs. 19%, p=0.01).

Finally, participants were asked to predict the results of ongoing BMT CTN clinical trials. In eight ongoing BMT CTN trials, 60% to 92% of respondents indicated that they thought a particular arm would be found to be superior at the end of the trial (Table 2) . Predictions for a specific intervention ranged from 44% to 88% in favor of the experimental arm being superior to conventional care. There was no clear relationship between the proportion predicting superiority of the experimental arm and accrual to the trial. Between 5% and 12% of the respondents indicated that they were not aware of specific clinical trials. Lack of awareness about the trials was more prevalent among HCT physicians practicing in non-BMT CTN core centers. Between 8% to 31% of the respondents practicing in non-BMT CTN core centers and between 5% to 13% of the respondents practicing in BMT CTN core centers report lack of awareness for the trials listed in table 2.

Among the clinical trials listed in Table 2 , the results of only a single trial (BMT CTN 1101, a multi-center phase II trial of reduced intensity conditioning followed by transplantation of either a double unrelated UCB graft or a Haplo bone marrow graft for patients with hematologic malignancies) was available at the time of survey data analysis (but not known at the time of the survey). Accrual to this trial lagged behind initial projections and eventually the accrual was closed at 94% of desired enrollment. The finding of this trial was that there was no significant difference observed in the 2-year progression-free survival (PFS) in the double UCB and Haplo bone marrow arms 3 . Approximately, one third of the respondents (36%) predicted similar PFS between the two arms of the study, whereas 44% and 15% of the survey participants predicted a better PFS with Haploidentical and umbilical cord, respectively. Nearly 5% reported lack of awareness for this clinical trial.

We We also found considerable variation in predictions among adult and pediatric HCT physicians including in anticipated numbers of HCT, preferences for graft and donor sources and GVHD prophylaxis strategies. Wide practice variation among adult and pediatric HCT physicians has been noted in prior survey studies 6 .

We also documented that a substantial minority of survey respondents (5-12%) were unaware of ongoing BMT CTN trials, though this was predominantly reported by clinicians in non-BMT CTN core centers. Only a small percentage of patients with cancer participate in clinical trials, which is due to many issues including lack of awareness that clinical trials are a treatment option. Health care providers play a major role in raising awareness about the option of clinical trial participation 7 . We believe this finding should encourage greater efforts to promote clinical trials awareness in community/non-BMT CTN centers, since participation on BMT CTN trials is not restricted to core centers.

We acknowledge several limitations of our study. Because of difficulties in defining the denominator of eligible physicians, the true estimate of actual survey response rate is not clear (between 32% and 85%) which is in line with the prior physician based survey studies 8, 9 . In addition, to ensure responders' anonymity, we cannot explore many of our findings further. For example, we cannot comment on any differences between respondents and non-respondents, and we did not collect data about institutional affiliations to explore whether predictions about the future of transplant was consistent within practice groups, whether center characteristics were associated with predictions, and whether predictions of trial results influence local accrual. We had hoped to gain insights about attitudes and accrual to trials but the data are too limited with only trials having reached completion of enrollment. This would be of interest to explore in future studies. Finally, although we have surveyed a large group of HCT clinicians, the majority of respondents practiced at a BMT CTN core or affiliate centers, which is not surprising since most transplant clinicians are participating with the BMTCTN trials at core or affiliate centers.

Thus, the survey results may largely represent the opinion of clinicians practicing in large academic centers.

In summary, transplant physicians see a bright future in their field but anticipate many changes will occur in the five years following the survey. We plan to return to these predictions in 2023 to see how closely they match reality. Of note, this survey was conducted prior to the novel coronavirus pandemic, and transplant practices have had to adapt to COVID-19 

While no one anticipated the COVID-19 crisis, 2023 is still a long time from now. It will be interesting to see if COVID-19 just created a pause in HCT or if it will

Blood and marrow transplant clinical trials network state of the Science Symposium

Current use and trends in hematopoietic cell transplantation in the united states

Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101). Blood

Practice patterns and preferences among hematopoietic cell transplantation clinicians

Current use of and trends in hematopoietic cell transplantation in the united states

Individual physician practice variation in hematopoietic cell transplantation

Public attitudes toward participation in cancer clinical trials

Exploring physician specialist response rates to web-based surveys

What do transplant physicians think about palliative care? A national survey study. Cancer